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In 2011-2014, the prevalence of HPV was higher in adult males compared to adult 
females. HPV and its associated health outcomes can be prevented through the completion of the 
3-dose HPV vaccine series. Using the 2010 - 2016 National Immunization Survey - Teen, I 
examined the association of family income and gender with three HPV vaccine utilization 
outcomes: (1) receipt of provider recommendation; (2) HPV vaccine initiation; and (3) HPV 
vaccine completion using logistic regressions. Results suggested that family income was 
negatively correlated with HPV vaccine outcomes regardless of gender and controlling for other 
covariates. I also found that males had lower vaccine use compared to females, regardless of 
income. In the second analysis I investigated if the 2011 ACIP guideline increased vaccine 
utilization outcomes using a difference-in-differences.  This analysis suggested that the 
new guideline increased recommendations by 24 percentage points for males, relative to females 
(P<0.01), HPV vaccine initiation improved by 23 percentage points (P<0.01), and vaccine 
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According to the Centers for Disease Control and Prevention (CDC) (2016), the human 
papillomavirus (HPV) is the most common sexually transmitted infection in the United States and 
it is estimated that approximately 90% of sexually active individuals will be infected at some point 
in their life. HPV can cause genital warts (from the low-high HPV strain) and cervical, anal, 
oropharynx, penile, vaginal, and vulvar cancers (from the high-risk HPV strain). Among adults, 
low levels of education and higher levels of poverty are associated with increased incidence rates 
of invasive HPV-associated cancers: cervical, penile, and vaginal (Benard et al., 2008) (Brisson, 
Drolet, & Malagón, 2013). 
HPV and its associated health outcomes can be prevented through the completion of the 
HPV vaccine, a three-dose series developed in June 2006. The doses are administered over a six 
month time-period (0, 2, 6 months) (“HPV Vaccine Administration | Human Papillomavirus 
Vaccination | CDC,” 2017) . Currently, there are three types of HPV vaccines: Cervarix, Gardasil, 
Gardasil-9.  They protect against two, four, and nine types of HPV, respectively. All of them 
protect against HPV 16 and 18, which are high risk strains and are responsible for most HPV-
associated cancers (National Institutes of Health, n.d.). In mid-2006, the Advisory Committee on 
Immunization Practices (ACIP) announced a recommendation that added the HPV vaccine to the 
routine immunization schedule for girls aged 9 to 26 years. In 2011, the ACIP included boys aged 
9 to 21 years to its routine HPV vaccination recommendation (Centers of Disease Control and 
Prevention, 2016). Males who identify as gay, bisexual, transgender, have sex with other males, 
or have an immunocompromising condition are recommended through age 26 (Centers of Disease 




As of 2016, ACIP altered the recommendation a two-dose HPV vaccine for adolescent 
females and males aged 11 or 12 (Meites, Kempe & Markowitz, 2016). Individuals who initiate 
prior to their 15th birthday is recommended for two doses. Those initiating on or after their 15th 
birthday is recommended to receive the full three dose series (Meites, Kempe & Markowitz, 2016).  
In 2016, the CDC estimated that 65% and 56% of girls and boys, respectively have initiated 
the series. However, only 43% of adolescents have completed the entire vaccination series (Centers 
of Disease Control and Prevention, 2017). Healthy People 2020 objectives aim to increase 
coverage of at least three doses of the HPV vaccine to 80% for adolescent males and females aged 
13 to 15 years. However, as of 2014, 39.7% and 21.6% of adolescent females and males, 
respectively, received at least three doses of the vaccine series (“Vaccination Coverage | NIS Teen 
| 2014 Maps by State | CDC,” 2017).  Increasing access and use of the HPV vaccine series remains 
an important public health goal. Full vaccine coverage would substantially reduce disease burden 
and associated health care costs. 
Background 
Fundamental Cause Theory 
The HPV vaccine is an example of a medical intervention created to reduce HPV associated 
conditions. For example, the HPV vaccine has reduced cervical cancer incidence and mortality, 
which in the past was the leading cause of cancer death among women in the United States 
(National Institutes of Health, n.d.). However, the American Cancer Society estimates that 13,240 
women will be newly diagnosed and 4,170 will die from cervical cancer in 2018 (American Cancer 
Society, 2018). A majority of cervical cancer cases were among minority and/or low 
socioeconomic status women. Non-Hispanic Black (11.3 per 100,000) and Hispanic (13.8 per 




(National Cancer Institute, n.d.). Similarly, racial and ethnic minorities are more likely to die from 
cervical cancer. Non-Hispanic Black women have the highest mortality rate (4.9 per 100,000) 
compared Hispanic (3.3 per 100,000) and non-Hispanic white women (2.3 per 100,000) (National 
Cancer Institute, n.d.). These disparities among minority women and/or women of lower 
socioeconomic status can be attributed to a variety of factors such as lack of healthcare coverage, 
knowledge, health literacy, access to primary care and/or diverse and culturally competent health 
care providers.  
 Though cervical cancer does not affect males, they are equally susceptible to low and high-
risk HPV in the form of genital warts and cancers of the oropharynx, anus, mouth, and penis. The 
prevalence of low and high risk HPV is higher among adult males compared to adult females. 
More recently, research has shown that oropharyngeal cancer among males has increased nearly 
300 percent in the past 40 years; there are approximate 12,638 new cases among males compared 
to 3,100 new cases among women every year (Sonawane et al., 2017).  In fact, the incidence of 
oropharyngeal cancer has surpassed the incidence of cervical cancer, making oropharyngeal cancer 
the most common HPV associated cancer in the United States (Sonawane et al., 2017).  
According to Phelan, Link, and Tehranifar (2010), the Fundamental Cause Theory was 
developed to explain health and mortality disparities related to socioeconomic status. Despite 
modern advancements in disease prevention and risk reduction the association between 
socioeconomic status, adverse health outcomes, and mortality persists (Link & Phelan, 1995).  
The Fundamental Cause Theory consists of four key features: [1] socioeconomic positions 
influences multiple diseases; [2] socioeconomic position is linked multiple proximate risk factors 
for these diseases; [3] the accessibility of resources that can reduce risks or can minimize the 




be replicated over time through the replacement of intervening mechanisms (Phelan, Link, & 
Tehranifar, 2010). HPV is a proximate risk factor for genital warts and HPV-associated cancers 
and the Fundamental Cause Theory predicts the onset of these health conditions and cancers by 
access to preventative methods, such as the HPV vaccine. 
In this study, I will test the Fundamental Cause Theory on adolescent male and female 
HPV vaccine utilization. The HPV vaccine is a medical intervention that is administered during 
adolescence and is the potential to reduce risk of genital warts and a variety of cancers affecting 
adult males and females. It can also produce socioeconomic position and race/ethnicity disparities 
in the incidence and mortality of HPV-associated conditions and cancers. The HPV vaccine can 
serve as an empirical test of the Fundamental Cause Theory because it introduces a shift in 
treatment and knowledge of HPV associated conditions and cancers. Prior to its debut in 2006, 
there were not any preventative methods for HPV. Second, given that the HPV vaccine is 
recommended for adolescents, the access and receipt of the vaccine is dependent upon the 
knowledge, consent, and socioeconomic status of their parents. Third, the vaccine is a one-time 
intervention (after completion of three dose series within six months) that is capable of preventing 
genital warts and HPV-associated cancers unlike other screenings such as the pap smear which 
requires regular adherence (Polonijo & Carpiano, 2013). 
It was expected that the HPV vaccination would significantly reduce the incidence of 
cervical cancer and other HPV associated cancers (“American Cancer Society Guideline for 
Human Papillomavirus (HPV) Vaccine Use to Prevent Cervical Cancer and Its Precursors - Saslow 
- 2007 - CA: A Cancer Journal for Clinicians - Wiley Online Library,” n.d.). However, groups 
with lower socioeconomic position and/or are racial-ethnic minorities are disproportionately 




the most from the vaccine, however they are the least likely to utilize the vaccine (Downs, Scarinci, 
Einstein, Collins, & Flowers, 2010). 
Polonijo and Carpiano (2013), tested the Fundamental Cause Theory in adolescent HPV 
vaccination inequalities, by focusing on the impact of socioeconomic position and race/ethnicity 
on HPV vaccination. They analyzed the association of socioeconomic position and race/ethnicity 
with parental knowledge of HPV, receipt of healthcare provider recommendation, and vaccination 
uptake (initiation and completion).  
Prevalence of Adult HPV 
In 2011-2014, the prevalence of any oral HPV (low risk and high risk) was 7.3% among 
adults aged 18 to 69 years, with 11.5% prevalence among males and 3.3% among females. In 
regard to high-risk oral HPV, the prevalence is 4% among all adults and 6.8% among males and 
1.2% among females (McQuillan, 2017). Overall, non-Hispanic Asian adults had a lower 
prevalence of high-risk oral HPV (1.7%) and among males (2.3%) compared to non-Hispanic 
White adults (4.2% overall and 7.3% males), non-Hispanic Black adults (4.3% overall and 7.5% 
males), and Hispanic adults (3.4% overall and 5.4% males) (McQuillan, 2017). 
Likewise, in 2011-2014, the prevalence of genital HPV was 42.5% among adults 18 to 69 
years and males had a higher prevalence (45.2%) than females (39.9%). Non-Hispanic Black 
adults has the highest prevalence compared to other racial-ethnic groups (64.1%) (McQuillan, 
2017). 
The prevalence of high-risk genital HPV was 22.7% among adults aged 18 to 69 years. The 
male prevalence was higher (25.1%) compared to females (20.4%). The prevalence of high-risk 
HPV is highest among all non-Hispanic Black adults (33.7% overall and 40.3% male) compared 




and 21.8% males), and non-Hispanic Asian adults (11.9% overall and 12.2% males) (McQuillan, 
2017).  
The Role of Family Income on HPV Vaccine Utilization 
 Per the Fundamental Cause Theory, it is expected that adolescents with lower family 
incomes would decreased utilization of the HPV vaccine compared to adolescents with higher 
family income. Niccolai et al. (2011) findings suggest that adolescents with family incomes below 
the federal poverty line (FPL) were less likely to initiate the vaccine series compared to adolescent 
with family incomes greater than $75,000. This study observed adolescent females aged 13 to 17 
years using the 2008 and 2009 National Immunization Survey-Teen (Niccolai, Mehta, & Hadler, 
2011).  Polonijo and Carpiano, (2013),  analyzed the association of household income on HPV 
vaccine knowledge, receipt of provider recommendation, initiation, and completion of the HPV 
vaccine series using the same income levels as Niccolai et al. (2011): below poverty level, greater 
than poverty level but less than or equal to $75,000, and greater than $75,000. Using the 2008, 
2009, and 2010 National Immunization Survey-Teen, Polonijio and Carpiano also found a positive 
correlation between household income and HPV vaccine initiation and completion, as well as, 
HPV vaccine knowledge and receipt of provider recommendation (Niccolai et al., 2011) (Polonijo 
& Carpiano, 2013). 
 On the contrary, Previous research suggests that low-income mothers view the HPV 
vaccine positively because they have had personal experiences with cervical cancer (Perkins, 
Pierre-Joseph, Marquez, Iloka, & Clark, 2010) (Gainforth Heather L., Cao Wei, & Latimer-
Cheung Amy E., 2012).  According to Jeudin et al. (2014), women who are living below the FPL 
have higher prevalence of HPV (56.5%)  compared to women who live above the FPL (39.7%) 




late-stages of cervical cancer and they are less likely to survive being diagnosed with a metastatic 
disease (Jeudin, Liveright, del Carmen, & Perkins, 2014). These findings influenced the study’s 
hypotheses. 
The Role of Healthcare Providers 
Similarly to parents and guardians, healthcare providers also play an integral role in 
adolescent HPV vaccination uptake as they can present barriers, implicitly or explicitly, that 
negatively impact the uptake of the HPV vaccine among adolescents. Barriers include inconsistent 
knowledge of the HPV vaccine among healthcare providers (Perkins & Clark, 2012) (Saraiya, 
Rosser, & Cooper, 2012), lack of understanding of the association between HPV and genital warts 
and/or the association between HPV and non-cervical cancers (Perkins & Clark, 2012) (Saraiya et 
al., 2012).  
Previous research has found that collaborative communication between providers and 
parents of adolescent girls improve the likelihood of HPV vaccination uptake (Moss, Gilkey, 
Rimer, & Brewer, 2016).  Moss et al. (2016), found that 53% of parents who completed the 2010 
NIS-Teen survey for their daughters reported having collaborative communications with their 
providers. This revealed that there were vast disparities in patient-provider collaborative 
communication. It was less likely to occur in underserved groups which accounted for differential 
utilization of the vaccine among adolescent girls. Patients who were poor, less-educated, Spanish 
speaking, southern, lived in rural areas, with non-privately insured parents, and identified as 
Hispanic reported less collaborative communication (Moss et al., 2016).  
The need for increased uptake of the HPV vaccine has generated research centered around 
immunization quality improvement in regards to adolescent health and cancer prevention (Gilkey 




of vaccine initiation relative to race/ethnicity, health insurance coverage status, knowledge of the 
HPV vaccine, and attitudes around the vaccine’s safety and effectiveness (Gilkey et al., 2016). In 
fact,  provider recommendation of the vaccine accounts for 70% of adolescent initiation of the 
series (Dorell, Yankey, Santibanez, & Markowitz, 2011).  
Gilkey et al. (2016), investigated the association of provider recommendation quality (no 
recommendation, low-quality, or high-quality) and found that 48% of parents in the study (N= 
1495) were not recommended the vaccine. They found that parents who received high-quality 
recommendations from provider had nine times the odds of initiating the series and three times the 
odds of completing the series compared to parents who did not receive a recommendation (Gilkey 
et al., 2016). As expected, they also found that parents who received a low-quality 
recommendation had four times the odds of initiating compared to parents who did not receive a 
recommendation, however, the odds of completing the series were not statistically distinguishable 
(Gilkey et al., 2016).  
HPV Vaccine Effectiveness and Dosage 
 The HPV vaccine is highly effective in preventing HPV types if received prior to exposure 
to the virus. Given the high prevalence of HPV, vaccines must be delivered prior to the onset of 
sexual activity, which on occurs at age 17.3 and 17 for females and males, respectively (Chandra, 
Martinez, Mosher, Abma, & Jones, 2005) (“Fertility, Contraception, and Fatherhood,” 2006). 
Clinical trials for Gardasil and Cervarix found that the vaccines protect against nearly 100% of 
cervical infections caused by HPV 16 and HPV 18 (“Human Papillomavirus (HPV) 
Vaccines”,  n.d.).  Similarly, Gardasil-9 is highly effective. Clinical trials found that the vaccine 




HPV types 31, 33, 45, 52, and 58 (“Human Papillomavirus (HPV) Vaccines,” n.d.) (Chatterjee, 
2014). 
 Gardasil and Cervarix are known to protect against their target HPV types for 8 (Ferris et 
al., 2014) and 9 (Naud et al., 2014) years, respectively. However, the duration of Gardasil-9 is 
unknown (“Human Papillomavirus (HPV) Vaccines,” n.d.). In regards to males, a Gardasil clinical 
trial found that it can prevent genital warts and anal cell changes caused by HPV infection 
(Giuliano et al., 2011).  Other studies have found that Cervarix is protective against  HPV 16 and 
18 infections within the anus (Kreimer et al., 2011) and oral cavity (Herrero et al., 2013) among 
women. 
 The HPV vaccine was originally recommended to be received in a three dose series over 
six months. Kreimer et al. (2011), found that the protection against HPV types 16 and 18 among 
women with one or two doses of Cervarix was comparable to women who received all three doses 
of the series, the research team also found that this protection persisted throughout four years of 
follow up (Kreimer et al., 2011). Similar studies have found that young adolescents who receive 
two doses of Cervarix and Gardasil have an immune response as strong as that of 15 to 25 years 
old individuals who received all three doses (Dobson et al., 2013) (Romanowski et al., 2011).  
Parental Acceptance 
Given that target age group for the vaccine is typically under 18, the receipt of the HPV 
vaccination is often dependent on the willingness and acceptance of their parents or guardians. 
Previous research has shown that a majority of parents are well aware the HPV vaccine (Joseph 
et al., 2012) (Tsui et al., 2013) (Litton, Desmond, Gilliland, Huh, & Franklin, 2011), however 
most parents lack knowledge and preferred more information prior to vaccinating their children; 




C. G. Dorell, Yankey, Santibanez, & Markowitz, 2011; C. Dorell, Yankey, & Strasser, 2011; 
Stokley et al., 2011; Gilkey, Moss, McRee, & Brewer, 2012; Joseph et al., 2012b; Kepka, Ulrich, 
& Coronado, 2012; Laz, Rahman, & Berenson, 2012; Oldach & Katz, 2012; Wilson, Brown, 
Boothe, & Harris, 2013; Hamlish, Clarke, & Alexander, 2012; Hofstetter & Rosenthal, 2014). 
Additional reluctance of the vaccine can be attributed to pharmaceutical involvement in ACIP 
recommendation, marketing of the vaccine, and quickness to incorporate the HPV vaccine into 
proposed school mandates and national vaccination program (Hofstetter & Rosenthal, 2014). 
Cultural Barriers to HPV Vaccine Uptake 
 Prior to the introduction of the HPV vaccine, socioeconomic disparities in cervical cancer 
persisted across countries worldwide (Fisher, Trotter, Audrey, MacDonald-Wallis, & Hickman, 
2013). In general, the disadvantaged women experienced higher incidence of cervical cancer 
compared to women who were more affluent women, this disparity persisted regardless of national 
cervical screening programs. The introduction of the HPV vaccine has broadened these health 
disparities (Fisher et al., 2013).  
Differential uptake of the HPV vaccine are can partially be attributed to cultural differences 
that predispose some groups, relative to others, to vaccine use. A small pilot study (n=12)  in 
Georgia found that Hispanic immigrant parents felt their immigration status, distrust in healthcare 
professionals and facility, as well as cultural factors prevented them from vaccinating their 
teenagers (Luque, Raychowdhury, & Weaver, 2012). Additionally, Joseph et al (2012), found that 
47% of African American and 31% of Haitian daughter have received the vaccine. This difference 
in uptake can be attributed to the increased awareness of HPV among African Americans compared 
to Haitian immigrants (Joseph et al., 2012). These finding reinforce the importance of 






Data was obtained from the National Immunization Survey—Teen (NIS-Teen), a 
nationally representative survey administered by the National Center for Immunization and 
Respiratory Diseases of the CDC. It was launched in 2006 and aims to provide estimates of current, 
population-based, state and local vaccination coverage among adolescents aged 13 to 17 years old 
(“NIS | About the National Immunization Surveys | Vaccines | CDC,” 2018).  The purpose of NIS-
Teen data is to monitor vaccination of adolescents at the national, state, and local level, as well as 
some US territories. In addition, the survey supports the Childhood Immunization Initiative by 
monitoring vaccine coverage and progress towards HealthyPeople 2020 objectives for adolescent 
immunizations (“A User’s Guide for the 2016 Public-Use Data File,” 2016). The data includes 
coverage of the tetanus, diphtheria, acellular pertussis (Tdap), quadrivalent meningococcal 
vaccine, (MenACWY) HPV, and the seasonal influenza vaccine. The analysis focused on 
adolescent females and males aged 13 to 17 years in the US, excluding territories. 
 Telephone numbers are selected using a complex sample design that includes stratification 
and clustering and is representative at estimation areas of residence (“A User’s Guide for the 2016 
Public-Use Data File,” 2016). Oversampling occurred for local areas: El Paso County, Texas and 
Dallas County, Texas. Currently, NIS-Teen used random digit dialing (RDD) to sample landline 
and cell-phone numbers. Each year uses independent, quarterly samples of landline or cell-phone 
numbers within estimation areas (“A User’s Guide for the 2016 Public-Use Data File,” 2016). 
During this study period (2010 – 2016), NIS-Teen underwent methodological changes which 




The addition of cell-phone accounts for the increase in households that solely use cell-phones (“A 
User’s Guide for the 2016 Public-Use Data File,” 2016). 
Data is collected through computer assisted telephone interviews of parents/guardians. 
Household with one or more adolescents aged 13 to 17 is selected, then one of the adolescents is 
randomly selected, and the parent or guardian who is most familiar with the selected adolescent’s 
immunization history is interviewed (“A User’s Guide for the 2016 Public-Use Data File,” 2016).  
Interview topics include: household-reported vaccination and health information; 
demographic/socioeconomic household/teen information, and geographic variables. 
 During the interview permission is sought from parents/guardians in order to collect data 
from the teens’ vaccinating healthcare providers. Providers are administered an Immunization 
History Questionnaire, which reports the types of vaccination received, number of doses, and dates 
of administration of the sampled adolescent. In addition, the Immunization History Questionnaire 
also collects data on the provider’s practice, including the type of healthcare facility. The response 
rate for the provider interviews ranges from 93.2 to 94.8% (“NIS - Datasets for the National 
Immunization Survey - Teen,” 2018), depending on the year. The  response rate, defined by the 
Council of American Survey Research Organization, of parents or guardians and is 22.4% to 
57.9%, depending on the year (“A User’s Guide for the 2016 Public-Use Data File,” 2016). The 
proportion of adolescents with adequate provider ranges from 47.4% to 59.4%, depending on the 
year (“A User’s Guide for the 2016 Public-Use Data File,” 2016). 
Independent Variables 
 The primary independent variables examined in Aims 1 and 2 are family income and sex. 
The family income was defined using income to poverty ratios, Each year utilized its respective 




federal poverty line (FPL), 200-399% of the FPL, and greater than or equal to 400% of the FPL. 
The gender variable was derived from the NIS-Teen variable describing the sex of the 
adolescent. The variable includes two categories: male and female. The independent variables of 
interest for Aim 3 are described in the analytic approach section. 
Dependent Variables 
 The dependent variables include provider recommendation, HPV vaccine initiation, and 
HPV vaccine completion. Provider recommendation was a binary indicator derived from a NIS-
Teen survey question that ask parents: “Provider recommendation comes from a survey question 
that asks parents: “Had or has doctor or other health care professional ever recommended that teen 
receive HPV shots?”  HPV vaccine initiation and vaccine completion comes from survey question: 
“Number of human papillomavirus shots / HPV-Gardasil / HPV-Gardasil 9 / HPV-Cervarix / HPV 
shots of unknown type by age 13 years” determined from provider info, excluding any vaccination 
after the teen interview date”. Vaccine initiation was coded as a binary indicator of at least one 
dose versus zero doses. Vaccine completion was coded as a 0/1 variable indicating three or more 
doses. The measure of the vaccine completion observed adolescents who received at least three 
doses out of all adolescents. 
 Prior to 2010, adolescent males were excluded from any HPV vaccine related questions. 
Initially, I planned to analyze NIS-Teen data from 2008 to 2016. However, due to the lack of data 
regarding adolescent males, years 2008 and 2009 were dropped and the analyzed was limited to 
years 2010 to 2016. 
Control Variables 
All analyses control for the following variables: race/ethnicity (Hispanic, non-Hispanic 




than 12 years, 12 years, more than 12 year but non-college graduate, and college graduate), health 
care coverage status  (uninsured, private, and public), census region (Northeast, Midwest, South, 
West), marital status (married and non-married), type of healthcare facility (usual place of care) 
(private, public, hospital, STD/school/teen clinics or others, and mixed) (See Appendix B through 
D).  
Analytic Approach 
 Aim 1 will measure the relationship between family income and the three HPV vaccine  
outcomes described above using multiple logistic regression. Control variables include gender, 
parental education, health insurance type, race/ethnicity, census region, marital status, and type of 
healthcare facility (see Appendix B). Results are reported as adjusted odds ratios (AOR). All 
models used survey weights to weight the sample with sufficient provider information to be 
representative of the U.S. teen population. Variance estimates adjusted for the complex sample 
design using Taylor series linearized standard errors. 
Aim 2 will measure the association between gender and outcomes using the same logistic 
regression framework described above. In addition separate stratified models were estimated for 
males and females separately to examine if income gradients differ by gender.  
Aim 3 will measure the impact of the 2011 ACIP recommendation on male HPV vaccine 
uptake by conducting a multivariable linear probability difference-in-differences analysis. The 
control group are adolescent females and the treatment group is adolescent males. Given that the 
new ACIP guideline was implemented in late 2011, the pre period included 2010 and 2011 and 
the post period included 2012 through 2016. The assumption of the difference-in-differences 
approach is that the trend for females represents the trend for males had they never been exposed 




unique to males and any national trends, common to both sexes, that could be confounded with the 
introduction of the guidelines. Figures 1, 2, and 3 describes the study’s conceptual framework for 
each of the specific aims (See Appendix A). 
Results 
Descriptive Statistics 
Tables 1 and 2 reports the descriptive statistics ( N = 263,401).  In regards to family income, 
41% of the population are less than 200% of the FPL, 52% are within 200% to 399% of the FPL, 
and 7% is greater than or equal to 400% of the FPL.  
The racial and ethnic delineation of the sample included 22% Hispanic, 55% non-Hispanic 
White, 14% non-Hispanic Black, and 9% identify as non-Hispanic, other and multiple races. 
Overall, 14% of the sample have mothers with less than 12 years of education, 27% of adolescents’ 
mothers have 12 years of education, 26% have more than 12 years with a bachelor’s degree, and 
36% are college graduates. 17% of the sample resides in the Northeast, 22% in the Midwest, 37% 
in the South, and 24% in the West. Lastly, 33% of adolescents within the sample have mothers 
who are married and 67% have mothers who are not married. 
Overall, 52.97% of the population received a provider recommendation for the HPV 
vaccine, 41.20% initiated the series, and 22.11% completed the HPV vaccine series. Table 1 
shows 49.20% of those less than 200% of the FPL, 56.39% of those between 200 and 399% of 
FPL, and 49.01% of those greater than 400% of the FPL were recommended for the HPV 
vaccine by a provider. Moreover, 43.67% of those less than 200%, 39.95% of those 200 to 
399%, and 36.73% of those greater than 400% of the FPL initiated the HPV vaccine series. 
Lastly, 21.41% of those less than 200% of FPL, 22.92% of those between 200 and 399% of FPL, 




When stratifying by gender, 38.45% of adolescent males received a recommendation 
compared to adolescent females (67.94%). Similarly, 28.07% of adolescent males initiated the 
series compared to adolescent females (54.66%), and 12.81% of adolescent males completed the 






The Association of Family Income and HPV Vaccine Utilization Outcomes 
Table 3 shows the results of the logistic regression of the HPV utilization outcomes: (1) provider 




pooled across all years in the study period. In regards to receipt of provider recommendation, 
adolescents with family incomes between 200 and 399% of the FPL have increased odds of 
receiving a provider recommendation compared to adolescents who have a family income greater 
than 400% of the FPL (AOR =1.16, P=0.04). Additionally, adolescents with the 200 to 399% 
(AOR = 1.23, P=0.01) and less than 200% of the FPL (AOR = 1.30, P<0.01) have increased 
odds of initiating the vaccine. Adolescents within the 200 to 399% of the FPL (AOR = 1.27, 
P=0.01) and less than 200% of the FPL (AOR=1.21, P=0.02) have increased odds of completing 
the series compared to those greater than 400% of the FPL. Vaccine completion is defined as 
adolescents who received at least three doses out of all adolescents. 
Hispanic adolescents have an increased odds of receiving a provider recommendation 
(AOR=1.16,  P<0.01), HPV vaccine initiation (AOR=1.45, P<0.01), and vaccine completion 
(AOR=1.22, P<0.01) compared to non-Hispanic White adolescents. Moreover, Table 3 shows 
that non-Hispanic Black have increased odds of initiating the series (AOR=1.12, P=0.01) and 
significantly reduced odds of completing the vaccine series (AOR=0.08, P=0.02) compared to 
non-Hispanic White adolescents. In regards to education of the adolescents’ mothers, mothers 
with less than 12 years, 12 years of education, and mothers with more than 12 years but without 
a college degree have significantly reduced odds of receiving a provider recommendation, 
initiating and completing the vaccination series compared to adolescents with mothers who 
graduated from college.  
I also found that publicly insured (AOR=0.77, P<0.01) and uninsured (AOR=0.61, 
P<0.01) adolescents have significantly reduced odds of receiving a provider recommendation 
compared to privately insured adolescents. Similarly, uninsured adolescents also have reduced 




series when compared to privately insured adolescents. The logistic regression also shows that 
adolescents that seek care from public facility (AOR=0.67, P<0.01) and STD/school/teen clinics 
or others (AOR=0.69, P<0.01) facilities have significantly reduced odds of receiving a provider 
recommendation compared to adolescents who seek care at private facilities. In addition, 
adolescents who seek care at public facilities (AOR=0.79, P<0.01) have reduced odds and 
adolescents who seek care at hospitals have increased odds (AOR=1.20, P<0.01) of initiating the 
series compared to adolescents that use private facilities. Lastly, adolescents who seek care at 
public  facilities (AOR=0.77, P<0.01) and STD/School/Teen Clinics or Others (AOR=0.73, 
P<0.01) have reduced odds of completing the series compared to adolescents who seek care at 
private facilities.  
Lastly, adolescents who reside in the Midwest, South, and Western regions of the United 
States have reduced odds of receiving a provider recommendation  and completing the HPV 
vaccine series compared to adolescents residing in the Northeast region of the United States. 
Similarly, adolescents in the Midwest and South have reduced odds of HPV vaccine initiation 
and completion compared to the Northeast. When observing the association between marital 
status and the three HPV vaccine utilization outcomes, I found that adolescents with non-married 
mothers had significant increased odds of receiving a provider recommendation (AOR=1.14, 
P<0.01), initiating (AOR=1.23, P<0.01), and completing the HPV vaccine series (AOR=1.11, 








The Association of Sex and HPV Vaccine Outcomes and Sex Specific Income Gradients  
Table 3 also demonstrates that adolescent males have statistically significant reduced 
odds of receiving a provider recommendation (AOR = 0.35, P<0.01), HPV vaccination initiation 





Tables 4 and 5 shows the results of gender specific regressions. Table 4 shows that 
among adolescent males, there is not statistical difference in provider recommendation or HPV 
vaccine completion by family income. However, male adolescents with less than 200% 
(AOR=1.22, P=0.05) of the FPL have increased odds of initiating the series compared to 
adolescents who are greater than 400% of the FPL.  
A similar phenomenon occurs among adolescent females (Table 5). Female adolescents 




P=0.01), initiating (AOR=1.36, P<0.01), and completing (AOR=1.32, P<0.01) the series 
compared to female adolescents who have a family income greater than 400% of the FPL. 
Similarly, female adolescents with a family income less than 200% of the FPL have increased 
odds of initiating (AOR=1.36, P<0.01) and completing (AOR=1.25, P<0.05)the vaccination 
series compared to those greater than 400% of the FPL. Further, female adolescents within 200 




to those above 400% of the FPL. The results presented in Tables 4 and 5 regarding the 
socioeconomic gradients suggest that the odds of receiving a provider recommendation, 




The Association of the ACIP Guideline for Males with HPV Vaccine Outcomes 
Figures 1, 2, and 3 
display a time series of the HPV 
vaccine utilization variables 
stratified by gender The red 
dashed line represents the 2011 
ACIP recommendation and the 
black line represents the 
beginning of the post-period of 
the difference in differences 
analysis.  
 Table 6 shows the effect of the 
2011 ACIP recommendation on 
adolescent male receipt of 
provider recommendation, 
HPV vaccine initiation, and 
HPV vaccine completion. 
Adolescent male receipt of 
provider recommendation 
increased 23 percentage points 
(P<0.01) during 2012 to 2016 
compared to 2010 to 2011, 




females. Similarly, adolescent male HPV vaccine initiation improved by 28 percentage point 
(P<0.01), and HPV vaccine completion improved by 12 percentage points (P<0.01).  




Family Income and HPV Vaccine Utilization Outcomes 
 Informed by the Fundamental Cause Theory, we hypothesized that adolescents with a 
lower family income would have reduced odds of receiving provider recommendation, HPV 
vaccination initiation, and vaccine completion. However, my findings negate my hypothesis and 
defies the Fundamental Cause Theory. I found that adolescents within the 200 to 399% of the 
FPL had increased odds of receiving a provider recommendation, initiating, and completing the 
vaccination series compared to adolescents with a family income greater than 400% of the FPL. 
Additionally, adolescents with less than 200% of the FPL had increased odds of initiating and 
completing the vaccine series compared to adolescents with a family income greater than 400% 
of the FPL.  
These findings contradict results reported by Niccolai et al. (2011) and Polonijo and 
Carpiano’s (2012) where they found that adolescents of lower family incomes had reduced odds 
of receiving provider recommendation, initiating, and completing the vaccine series. The 
difference in our finding can be attributed to using different time periods of data. I used six years 
of data (2010 to 2016) and the data I analyzed was more reliable because providers verified the 
responses of parents or guardians. 
Given that family income and educational attainment are correlated (Jeudin et al., 2014). 
I was surprised that our findings related to parental education did not agree with the findings 
regarding family income. Our findings align with Polonijo and Carpiano (2010), adolescents 
with lower parental education had significantly reduced odds of the HPV vaccine utilization 
outcomes compared to adolescents with mothers who graduated from college. These findings 
contradict with Jeudin et al. (2014), who found that mothers who had a high school diploma or 




degrees. These difference in findings may be an indication that maternal education is not a strong 
indicator of the HPV vaccine utilization outcomes as it does not necessarily reflect the highest 
level of educational attainment within the household whereas family income has the potential to 
be a more accurate indicator of socioeconomic position.  
Unlike, Jeudin et al. (2014), Polonijo and Carpiano (2010), and Niccolai et al. (2011) our 
study included adolescent males in the analysis. The inclusion of adolescent males may be 
skewing the association of maternal education and HPV vaccine utilization outcomes., All of 
these study focus solely on the role of the mother’s education excluding the potential role father 
play on the HPV vaccine utilization outcomes. Future studies should examine the role the father 
plays on HPV vaccine uptake for adolescent males and females. Additionally, future studies 
should explore if mothers and fathers have differential impact on receipt of provider 
recommendation, HPV vaccine initiation, and completion. 
Gender and HPV Vaccine Utilization Outcomes 
Aim 2 measured the association between gender and the HPV utilization outcomes and 
explored if socioeconomic gradients in HPV utilizations were consistent across genders, I 
hypothesized that adolescent males would have reduced odds compared to adolescent females 
and that adolescents with lower family income would have reduced odds of the three HPV 
vaccination outcomes compared to those with higher family income. Findings from Table 3 
support our hypothesis regarding reduced adolescent male vaccination. However, Tables 4 and 5, 
continue to defy the Fundamental Cause Theory as adolescent males with family incomes less 
than 200% of the FPL have increased odds of initiating the vaccination series compared to 
adolescent males with incomes greater than 400% of the FPL. A similar trend occurs among 




increased odds of all three outcomes when compared to adolescent females with family incomes 
greater than 400% of the FPL. Likewise, adolescent females with family incomes less than 200% 
of the FPL have increased odds initiating and completing the HPV vaccine series compared to 
adolescent females with family incomes greater than 400% of the FPL 
Understanding patient-provider communication experiences among adolescent males and 
their families could explain the low utilization of the HPV among adolescent males. Exposing 
this can provide practical and policy implications to improve uptake and coverage of the vaccine 
in young males. Per Gilkey et al. (2016) findings, high quality provider recommendation 
significantly improved the odds of initiating and completing the vaccine series compared to low-
quality or no provider recommendation.  
Therefore, there is a need to educate pediatricians on effective recommendation tactics 
for parents and guardians of adolescent males. There is also a need to ensure that all pediatricians 
are aware of the impact of HPV on males and the need for male vaccine uptake as males have 
been equally susceptible to HPV.  Given that there is no routine HPV preventative screening 
mechanism for males, they can serve as a vehicle in the transmission of HPV if uptake does not 
improve.  
Effect of 2011 ACIP Recommendation on HPV Vaccine Utilization Outcomes 
Lastly, in Aim 3,  measured the effect of the 2011 ACIP on adolescent male HPV vaccine 
utilization outcomes. Table 6 shows that there was a significant increase in all of the male 
adolescent HPV vaccine utilization series before and after the 2011 ACIP recommendation. The 
magnitude of the increase in male receipt of provider recommendation and HPV vaccine 
initiation is moderate, while the increase in HPV vaccine completion was mild. Even though, 




there is still a need for improvement on each of these outcomes especially when considering 
adolescent females HPV outcomes since the HPV vaccine became a routine immunization for 
females in 2006.  
Study Limitations 
 Limitations of the study relate to methodologic changes of the NIS-Teen survey. In 2011, 
cell-phones were added to the sampling frame, which prior to 2011, previously only utilized 
landline phones (“A User’s Guide for the 2016 Public-Use Data File,” 2016).  The addition of 
cell-phones to the sampling frame potentially increased the representation of younger parents or 
guardians. Younger parents or guardians could have different views of the HPV vaccine 
compared to older parents or guardian, which could also explain the difference in our study’s 
findings compared to older studies that used data prior to 2011. 
Moreover, the definition of adequate provider data (APD) changed in 2014 (Reagan-
Steiner et al., 2015). As of 2014, all coverage estimates are based on provider-reported 
immunization records. The revised APD definition has affected the vaccine coverage estimates 
along with characteristics of the adolescents in the sample, in fact, it decreased coverage 
estimates of the HPV vaccine (Reagan-Steiner et al., 2015). However, I consulted directly with 
NIS-Teen affiliated statisticians at the CDC about the potential implications of the sample frame 
and adequate provider definition and they expressed little concern that these survey design 
changes adversely impacted the time series. 
  A related issue had to do with the exclusion of males from the HPV questions in years 
2008 and 2009. This particularly affected the pre-period (2010 to 2011) of the difference in 




in the HPV vaccine utilization outcomes to the 2011 ACIP recommendation. Specifically, I was 
unable to fully examine if pre-period trends were similar for males and females. 
Study Implications 
Though the 2011 ACIP recommendation is associated with an increase in receipt of 
provider recommendation, HPV vaccine initiation, and completion among adolescent males there 
are still significant differences in these outcomes compared to adolescent females. Given that the 
prevalence of low and high risk HPV is higher among adult males compared to adult females, it 
is imperative that the utilization of the vaccine is improved among adolescents of all genders 
prior to sexual debut. 
 The initiation and completion of the series is likely dependent on the receipt of a 
provider recommendation (Gilkey et al., 2016) (Moss, Gilkey, Rimer, & Brewer, 2016). Future 
studies should aim to further understand adolescent males uptake of the vaccine, especially as it 
related to patient-provider communication. Along with studying parents or guardian knowledge 
and acceptance of the vaccine for their son(s), it is also crucial to ensure that providers are also 
aware of the need for adolescent male HPV vaccination and are trained to educate and encourage 
parents or guardians to vaccine their son(s).  
In addition to further research, health promotion, and interventions, our findings suggest 
the need for an HPV vaccine mandate for school-aged or college-aged students. The Healthy 
People 2020 objectives Immunization and Infectious Diseases-11.4 and 11.5 aims to increase the 
coverage of at least three of the HPV vaccine for adolescent females and males ages 13 to 15 
years to 80% (“Immunization and Infectious Diseases | Healthy People 2020,” n.d.). The vaccine 
became a routine recommendation for girls in 2006 and boys in 2011, and uptake has been low 




and males, respectively, aged 13 to 17 years have received at least three doses of the vaccine 
series (“Vaccination Coverage | NIS Teen | 2014 Maps by State | CDC,” 2017).   
Our finding that family income was inversely related to vaccine outcomes was surprising. 
Our motivating theory was that lower income individuals would be excluded from resources that 
enable health service use, including HPV vaccine use. However, our data suggest the opposite 
pattern. It is likely that this pattern is driven by the fact that the HPV vaccine is a controversial as 
it related to sexual activity and preventing a sexual transmitted infection that could cause genital 
warts or cancer. On top of the vaccine being tied to sexual activity, it is highly recommended to 
be taken as early as the age of nine. It is possible that lower income parents had or knows 
someone who has had personal experiences with sexual transmitted infections or HPV-associated 
cancers and therefore are more understanding or more realistic about the potential for their 
children’s sexual debut or activity. On the other hand, it is possible that lower income parents do 
not have access to the information that may hinder more affluent parents from having their 
children vaccinated, such as effectiveness, side effects, or adverse health events related to uptake 
of the vaccine.  
Since the vaccine was issued in 2006, a plethora of research has been published around 
understanding and improving parental acceptance, willingness, and barriers to HPV vaccine 
uptake through community-based interventions, however, the rates of uptake of been slowly 
increasing over the past 12 years. A mandate for school-aged children would ensure that the 
vaccine is initiated and completed but more importantly, vaccinating school-aged children is the 
most effective way of preventing most HPV strains because the vaccine will be received prior to 
sexual debut. From a population health standpoint, mandating the vaccine for school-aged 




ultimate reduce the onset of genital warts and HPV-associated cancer, such as oropharyngeal 














































Appendix B: Variable Table for Aim 1 








• Income to poverty 
ratio (recode) 
 
















• Number of HH-reported 
Human Papillomavirus 
shots received (total) 
• Number of HH-reported 
Human Papillomavirus 
shots received (total) 
 
•  Had or has doctor or other 
healthcare professional 
ever recommended that 
teen receive HPV shots? 
Effect Modifying  
Variables 
• Race/Ethnicity • RACEETHK 
 
• Race/ethnicity of teen with 
multirace category 
(recode) 
Moderator Variables • Parent Education 
 








• Education level of mother 
with 4 categories 





• Marital Status 
 










• Marital status of mother 
(recode) 
• Facility types for teen’s 
providers 
 
• Census region based on 





















Appendix C: Variable Table for Aim 2 







• Sex of teen 
 
















• Number of HH-reported 
Human Papillomavirus 
shots received (total) 
• Number of HH-reported 
Human Papillomavirus 
shots received (total) 
 
•  Had or has doctor or other 
healthcare professional 
ever recommended that 
teen receive HPV shots? 
Effect Modifying  
Variables 
• Race/Ethnicity • RACEETHK 
 
• Race/ethnicity of teen with 
multirace category 
(recode) 
Moderator Variables • Parent Education 
 
• Family Income 
 
 







• Education level of mother 
with 4 categories 
• Income to poverty ratio 
(recode) 















• Facility types for teen’s 
providers 
 
• Census region based on 























Appendix D: Variable Table for Aim 3 







• Sex of teen 
 
















• Number of HH-reported 
Human Papillomavirus 
shots received (total) 
• Number of HH-reported 
Human Papillomavirus 
shots received (total) 
 
• Had or has doctor or other 
healthcare professional 
ever recommended that 
teen receive HPV shots? 







• Race/ethnicity of teen with 
multirace category 
(recode) 
• Sampling year 
Moderator Variables • Parent Education 
 




• Education level of mother 






• Marital Status 
 












• Income to poverty ratio 
(recode) 
• Marital status of mother 
(recode) 
• Facility types for teen’s 
providers 
 
Census region based on true 


















American Cancer Society Guideline for Human Papillomavirus (HPV) Vaccine Use to Prevent 
Cervical Cancer and Its Precursors - Saslow - 2007 - CA: A Cancer Journal for Clinicians 
- Wiley Online Library. (n.d.). Retrieved February 5, 2018, from 
https://www.ncbi.nlm.nih.gov/pubmed/17237032. 
Bastani, R., Glenn, B. A., Tsui, J., Chang, L. C., Marchand, E. J., Taylor, V. M., & Singhal, R. 
(2011). Understanding suboptimal human papillomavirus vaccine uptake among ethnic 
minority girls. Cancer Epidemiology, Biomarkers & Prevention: A Publication of the 
American Association for Cancer Research, Cosponsored by the American Society of 
Preventive Oncology, 20(7), 1463–1472. https://doi.org/10.1158/1055-9965.EPI-11-0267 
Chatterjee, A. (2014). The next generation of HPV vaccines: nonavalent vaccine V503 on the 
horizon. Expert Review of Vaccines, 13(11), 1279–1290. 
https://doi.org/10.1586/14760584.2014.963561 
Dobson, S. R. M., McNeil, S., Dionne, M., Dawar, M., Ogilvie, G., Krajden, M., … Young, E. 
(2013). Immunogenicity of 2 doses of HPV vaccine in younger adolescents vs 3 doses in 
young women: a randomized clinical trial. JAMA, 309(17), 1793–1802. 
https://doi.org/10.1001/jama.2013.1625 
Dorell, C. G., Yankey, D., Santibanez, T. A., & Markowitz, L. E. (2011). Human papillomavirus 





Dorell, C., Yankey, D., & Strasser, S. (2011). Parent-reported reasons for nonreceipt of 
recommended adolescent vaccinations, national immunization survey: teen, 2009. 
Clinical Pediatrics, 50(12), 1116–1124. https://doi.org/10.1177/0009922811415104 
Downs, L. S., Scarinci, I., Einstein, M. H., Collins, Y., & Flowers, L. (2010). Overcoming the 
barriers to HPV vaccination in high-risk populations in the US. Gynecologic Oncology, 
117(3), 486–490. https://doi.org/10.1016/j.ygyno.2010.02.011 
Ferris, D., Samakoses, R., Block, S. L., Lazcano-Ponce, E., Restrepo, J. A., Reisinger, K. S., … 
Saah, A. (2014). Long-term study of a quadrivalent human papillomavirus vaccine. 
Pediatrics, 134(3), e657-665. https://doi.org/10.1542/peds.2013-4144 
Gilkey, M. B., Moss, J. L., McRee, A.-L., & Brewer, N. T. (2012). Do correlates of HPV vaccine 
initiation differ between adolescent boys and girls? Vaccine, 30(41), 5928–5934. 
https://doi.org/10.1016/j.vaccine.2012.07.045 
Giuliano, A. R., Palefsky, J. M., Goldstone, S., Moreira, E. D., Penny, M. E., Aranda, C., … 
Guris, D. (2011). Efficacy of quadrivalent HPV vaccine against HPV Infection and 
disease in males. The New England Journal of Medicine, 364(5), 401–411. 
https://doi.org/10.1056/NEJMoa0909537 
Hamlish, T., Clarke, L., & Alexander, K. A. (2012). Barriers to HPV immunization for African 
American adolescent females. Vaccine, 30(45), 6472–6476. 
https://doi.org/10.1016/j.vaccine.2012.07.085 
Herrero, R., Quint, W., Hildesheim, A., Gonzalez, P., Struijk, L., Katki, H. A., … CVT Vaccine 
Group. (2013). Reduced prevalence of oral human papillomavirus (HPV) 4 years after 





Hofstetter, A. M., & Rosenthal, S. L. (2014). Factors impacting HPV vaccination: lessons for 
health care professionals. Expert Review of Vaccines, 13(8), 1013–1026. 
https://doi.org/10.1586/14760584.2014.933076 
Human Papillomavirus (HPV) Vaccines. (n.d.). [cgvFactSheet]. Retrieved February 17, 2018, 
from https://www.cancer.gov/about-cancer/causes-prevention/risk/infectious-agents/hpv-
vaccine-fact-sheet 
Joseph, N. P., Clark, J. A., Bauchner, H., Walsh, J. P., Mercilus, G., Figaro, J., … Perkins, R. B. 
(2012a). Knowledge, Attitudes, and Beliefs Regarding HPV Vaccination: Ethnic and 
Cultural Differences Between African-American and Haitian Immigrant Women. 
Women’s Health Issues, 22(6), e571–e579. https://doi.org/10.1016/j.whi.2012.09.003 
Kepka, D. L., Ulrich, A. K., & Coronado, G. D. (2012). Low knowledge of the three-dose HPV 
vaccine series among mothers of rural Hispanic adolescents. Journal of Health Care for 
the Poor and Underserved, 23(2), 626–635. https://doi.org/10.1353/hpu.2012.0040 
Kreimer, A. R., González, P., Katki, H. A., Porras, C., Schiffman, M., Rodriguez, A. C., … CVT 
Vaccine Group. (2011). Efficacy of a bivalent HPV 16/18 vaccine against anal HPV 
16/18 infection among young women: a nested analysis within the Costa Rica Vaccine 
Trial. The Lancet. Oncology, 12(9), 862–870. https://doi.org/10.1016/S1470-
2045(11)70213-3 
Laz, T. H., Rahman, M., & Berenson, A. B. (2012). An update on human papillomavirus vaccine 
uptake among 11-17 year old girls in the United States: National Health Interview 
Survey, 2010. Vaccine, 30(24), 3534–3540. https://doi.org/10.1016/j.vaccine.2012.03.067 
Link, B. G., & Phelan, J. (1995). Social conditions as fundamental causes of disease. Journal of 




Litton, A. G., Desmond, R. A., Gilliland, J., Huh, W. K., & Franklin, F. A. (2011). Factors 
associated with intention to vaccinate a daughter against HPV: a statewide survey in 
Alabama. Journal of Pediatric and Adolescent Gynecology, 24(3), 166–171. 
https://doi.org/10.1016/j.jpag.2011.01.004 
Luque, J. S., Raychowdhury, S., & Weaver, M. (2012). Health care provider challenges for 
reaching Hispanic immigrants with HPV vaccination in rural Georgia. Rural and Remote 
Health, 12(2), 1975. 
McQuillan G, Kruszon-Moran D, Markowitz LE, Unger ER., Paulose-Ram R. Prevalence of 
 HPV in adults aged 18–69: United States, 2011–2014. NCHS data brief, no 280. 
 Hyattsville, MD: National Center for Health Statistics. 2017. 
Moss, J. L., Gilkey, M. B., Rimer, B. K., & Brewer, N. T. (2016). Disparities in collaborative 
patient-provider communication about human papillomavirus (HPV) vaccination. Human 
Vaccines & Immunotherapeutics, 12(6), 1476–1483. 
https://doi.org/10.1080/21645515.2015.1128601 
Naud, P. S., Roteli-Martins, C. M., De Carvalho, N. S., Teixeira, J. C., de Borba, P. C., Sanchez, 
N., … Descamps, D. (2014). Sustained efficacy, immunogenicity, and safety of the HPV-
16/18 AS04-adjuvanted vaccine: final analysis of a long-term follow-up study up to 9.4 
years post-vaccination. Human Vaccines & Immunotherapeutics, 10(8), 2147–2162. 
https://doi.org/10.4161/hv.29532 
Oldach, B. R., & Katz, M. L. (2012). Ohio Appalachia public health department personnel: 
human papillomavirus (HPV) vaccine availability, and acceptance and concerns among 





Perkins, R. B., & Clark, J. A. (2012). Providers’ attitudes toward human papillomavirus 
vaccination in young men: challenges for implementation of 2011 recommendations. 
American Journal of Men’s Health, 6(4), 320–323. 
https://doi.org/10.1177/1557988312438911 
Phelan, J. C., Link, B. G., & Tehranifar, P. (2010). Social conditions as fundamental causes of 
health inequalities: theory, evidence, and policy implications. Journal of Health and 
Social Behavior, 51 Suppl, S28-40. https://doi.org/10.1177/0022146510383498 
Polonijo, A. N., & Carpiano, R. M. (2013). Social inequalities in adolescent human 
papillomavirus (HPV) vaccination: a test of fundamental cause theory. Social Science & 
Medicine (1982), 82, 115–125. https://doi.org/10.1016/j.socscimed.2012.12.020 
Romanowski, B., Schwarz, T. F., Ferguson, L. M., Peters, K., Dionne, M., Schulze, K., … 
Descamps, D. (2011). Immunogenicity and safety of the HPV-16/18 AS04-adjuvanted 
vaccine administered as a 2-dose schedule compared with the licensed 3-dose schedule: 
results from a randomized study. Human Vaccines, 7(12), 1374–1386. 
https://doi.org/10.4161/hv.7.12.18322 
Saraiya, M., Rosser, J. I., & Cooper, C. P. (2012). Cancers that U.S. physicians believe the HPV 
vaccine prevents: findings from a physician survey, 2009. Journal of Women’s Health 
(2002), 21(2), 111–117. https://doi.org/10.1089/jwh.2011.3313 
Sonawane, K., Suk, R., Chiao, E. Y., Chhatwal, J., Qiu, P., Wilkin, T., … Deshmukh, A. A. 
(2017). Oral Human Papillomavirus Infection: Differences in Prevalence Between Sexes 
and Concordance With Genital Human Papillomavirus Infection, NHANES 2011 to 




Stokley, S., Cohn, A., Dorell, C., Hariri, S., Yankey, D., Messonnier, N., & Wortley, P. M. 
(2011). Adolescent vaccination-coverage levels in the United States: 2006-2009. 
Pediatrics, 128(6), 1078–1086. https://doi.org/10.1542/peds.2011-1048 
Tsui, J., Gee, G. C., Rodriguez, H. P., Kominski, G. F., Glenn, B. A., Singhal, R., & Bastani, R. 
(2013). Exploring the role of neighborhood socio-demographic factors on HPV vaccine 
initiation among low-income, ethnic minority girls. Journal of Immigrant and Minority 
Health, 15(4), 732–7A User’s Guide for the 2016 Public-Use Data File. (2016), 219. 
Benard, V. B., Johnson, C. J., Thompson, T. D., Roland, K. B., Lai, S. M., Cokkinides, V., … 
Weir, H. K. (2008). Examining the association between socioeconomic status and 
potential human papillomavirus-associated cancers. Cancer, 113(10 Suppl), 2910–2918. 
https://doi.org/10.1002/cncr.23742 
Brisson, M., Drolet, M., & Malagón, T. (2013). Inequalities in Human Papillomavirus (HPV)–
Associated Cancers: Implications for the Success of HPV Vaccination. JNCI: Journal of 
the National Cancer Institute, 105(3), 158–161. https://doi.org/10.1093/jnci/djs638 
Chandra, A., Martinez, G. M., Mosher, W. D., Abma, J. C., & Jones, J. (2005). Fertility, family 
planning, and reproductive health of U.S. women: Data from the 2002 National Survey of 
Family Growth [Data set]. American Psychological Association. 
https://doi.org/10.1037/e414702008-001 
Dorell, C. G., Yankey, D., Santibanez, T. A., & Markowitz, L. E. (2011). Human papillomavirus 





Fertility, Contraception, and Fatherhood: Data on Men and Women From Cycle 6 (2002) of the 
National Survey of Family Growth: (610122007-001). (2006). [Data set]. American 
Psychological Association. https://doi.org/10.1037/e610122007-001 
Fisher, H., Trotter, C. L., Audrey, S., MacDonald-Wallis, K., & Hickman, M. (2013). 
Inequalities in the uptake of Human Papillomavirus Vaccination: a systematic review and 
meta-analysis. International Journal of Epidemiology, 42(3), 896–908. 
https://doi.org/10.1093/ije/dyt049 
Gainforth Heather L., Cao Wei, & Latimer-Cheung Amy E. (2012). Message Framing and 
Parents’ Intentions to have their Children Vaccinated Against HPV. Public Health 
Nursing, 29(6), 542–552. https://doi.org/10.1111/j.1525-1446.2012.01038.x 
Gilkey, M. B., Calo, W. A., Moss, J. L., Shah, P. D., Marciniak, M. W., & Brewer, N. T. (2016). 
Provider communication and HPV vaccination: The impact of recommendation quality. 
Vaccine, 34(9), 1187–1192. https://doi.org/10.1016/j.vaccine.2016.01.023 
Hariri, S., Unger, E. R., Sternberg, M., Dunne, E. F., Swan, D., Patel, S., & Markowitz, L. E. 
(2011). Prevalence of Genital Human Papillomavirus Among Females in the United 
States, the National Health and Nutrition Examination Survey, 2003–2006. The Journal 
of Infectious Diseases, 204(4), 566–573. https://doi.org/10.1093/infdis/jir341 
HPV Vaccine Administration | Human Papillomavirus Vaccination | CDC. (2017, November 
27). Retrieved April 7, 2018, from 
https://www.cdc.gov/vaccines/vpd/hpv/hcp/administration.html 






Jeudin, P., Liveright, E., del Carmen, M. G., & Perkins, R. B. (2014). Race, Ethnicity, and 
Income Factors Impacting Human Papillomavirus Vaccination rates. Clinical 
Therapeutics, 36(1), 24–37. https://doi.org/10.1016/j.clinthera.2013.11.001 
Joseph, N. P., Clark, J. A., Bauchner, H., Walsh, J. P., Mercilus, G., Figaro, J., … Perkins, R. B. 
(2012). Knowledge, Attitudes, and Beliefs Regarding HPV Vaccination: Ethnic and 
Cultural Differences Between African-American and Haitian Immigrant Women. 
Women’s Health Issues, 22(6), e571–e579. https://doi.org/10.1016/j.whi.2012.09.003 
Moss, J. L., Gilkey, M. B., Rimer, B. K., & Brewer, N. T. (2016). Disparities in collaborative 
patient-provider communication about human papillomavirus (HPV) vaccination. Human 
Vaccines & Immunotherapeutics, 12(6), 1476–1483. 
https://doi.org/10.1080/21645515.2015.1128601 
Niccolai, L. M., Mehta, N. R., & Hadler, J. L. (2011). Racial/Ethnic and poverty disparities in 
human papillomavirus vaccination completion. American Journal of Preventive 
Medicine, 41(4), 428–433. https://doi.org/10.1016/j.amepre.2011.06.032 
NIS | About the National Immunization Surveys | Vaccines | CDC. (2018, January 30). Retrieved 
April 6, 2018, from https://www.cdc.gov/vaccines/imz-managers/nis/about.html 
NIS - Datasets for the National Immunization Survey - Teen. (2018, March 22). Retrieved April 
7, 2018, from https://www.cdc.gov/nchs/nis/data_files_teen.htm 
Perkins, R. B., Pierre-Joseph, N., Marquez, C., Iloka, S., & Clark, J. A. (2010). Why Do Low-
Income Minority Parents Choose Human Papillomavirus Vaccination for Their 





Polonijo, A. N., & Carpiano, R. M. (2013). Social inequalities in adolescent human 
papillomavirus (HPV) vaccination: a test of fundamental cause theory. Social Science & 
Medicine (1982), 82, 115–125. https://doi.org/10.1016/j.socscimed.2012.12.020 
Reagan-Steiner, S., Elam-Evans, L. D., Singleton, J. A., Copeland, K. R., Liu, L., Skalland, B., 
& Wolter, K. M. (2015). National Immunization Survey-Teen (NIS-Teen): Revised 
definition of Adequate Provider Data, 8. 
Sonawane, K., Suk, R., Chiao, E. Y., Chhatwal, J., Qiu, P., Wilkin, T., … Deshmukh, A. A. 
(2017). Oral Human Papillomavirus Infection: Differences in Prevalence Between Sexes 
and Concordance With Genital Human Papillomavirus Infection, NHANES 2011 to 
2014. Annals of Internal Medicine, 167(10), 714–724. https://doi.org/10.7326/M17-1363 
Vaccination Coverage | NIS Teen | 2014 Maps by State | CDC. (2017, April 27). Retrieved April 
7, 2018, from https://www.cdc.gov/vaccines/imz-
managers/coverage/nis/teen/figures/2014-map.html 
40. https://doi.org/10.1007/s10903-012-9736-x 
Wilson, R., Brown, D. R., Boothe, M. A. S., & Harris, C. E. S. (2013). Knowledge and 
acceptability of the HPV vaccine among ethnically diverse black women. Journal of 
Immigrant and Minority Health, 15(4), 747–757. https://doi.org/10.1007/s10903-012-
9749-5 
 
